Since the pioneering studies of Huggins in 1941, it has been known that prostate cancer cells, like certain normal epithelial cells, can chronically depend on a critical level of androgenic stimulation for their continuous growth and survival. The entire issue of the development of resistance to androgen ablation therapy for metastatic prostate cancer is based on the fact that a portion of cells can survive without androgen stimulation. The cell mechanism of androgen independent status is unclear. For some authors, a portion of the cells present within a patient with a prostate cancer before therapy is naturally androgen independent (selection hypothesis). However, this hypothesis does not consider gene alteration during prostate cancer natural history and probably hormone-refractory prostate cancer (HRPC) is due to a multi-step and multi-event process. In this literature review, different cell pathways that lead to HRPC are described.
Introduction
Cancer of the prostate gland is the most frequently diagnosed malignancy in men. In western countries 1% of all deaths and 13% of deaths from cancer are due to prostate cancer. The incidence and mortality of this malignancy are increasing more rapidly than life expectancy despite earlier diagnosis. 1 Prostate cancer is still often discovered at a locally advanced stage (exceeding the limits of the gland) or when already metastatic. At this stage there is no curative therapy. 2, 3 The treatment of metastatic prostate cancer is based on androgen deprivation, since Huggins demonstrated the androgen dependency of this malignancy. 4, 5 Currently, the term 'hormone therapy' covers all treatments that lead to a fall in androgen levels or counter the action of these sex steroids. These treatments usually lead to a reduction in the volume of the prostate and sometimes the metastases too. They occasionally induce spectacular remission from the clinical manifestations of prostate cancer. However, it very rapidly emerged that hormone therapy is only palliative in most patients and that the tumour becomes 'hormone-resistant' after a certain period.
How can prostate cancer cells become resistant to hormone deprivation? The first hypothesis is from Isaacs et al 6 who supposed that there is in the prostate before castration both cell phenotypes: hormone-sensitive and hormonerefractory (HRPC: hormone-refractory prostate cancer). The castration effect is to select the hormone-refractory prostate cells (the selection hypothesis). However, this hypothesis cannot explain the molecular alterations that are observed during prostate cancer's natural history and probably HRPC is due to a multi-step and multi-event process. In this literature review, different cell pathways that lead to HRPC are described.
The selection hypothesis
For Isaacs et al 6, 7 within the normal prostate, the glandular epithelial and a subset of endothelial cells are andro-gen-dependent because, without sufficient levels of circulating androgen, their rate of cell proliferation is lower than their rate of cell death ( Figure 1 ). These dependent cells are thus eliminated by androgen ablation. In contrast, the prostatic basal cells are not androgen-dependent because they are not eliminated following castration. Indeed, the stem cells within this basal cell compartment are androgen-independent in that their rates of proliferation and death are unaffected by androgen ablation. Also in this basal cell compartment are amplifying cells that, although not androgen-dependent (ie not eliminated by androgen ablation), have a rate of cell proliferation that is enhanced by androgen over their rate of cell death (ie the cells are androgen-sensitive but not androgen-dependent). Indeed, the androgen sensitivity of these amplifying cells allows exogenous androgen replacement to induce proliferative restoration of the androgen-dependent glandular cell compartment in the prostate of previously castrated hosts. The normal prostate epithelial compartment is composed of hierarchically expanding stem cell units. The prostate is heterogeneously composed of a limited number of androgen-independent stem cells that, besides maintaining their own limited numbers, give rise to a larger subset of progeny that differentiate into the androgen-independent but sensitive amplifying cells. When sufficient androgen is not present (ie following androgen ablation), the amplifying cells are maintained (ie rate of proliferation equals rate of cell death) but do not expand into transit cells. In contrast, when physiologically normal levels of androgen are exogenously replaced in a previously castrated host, the majority of these androgen-sensitive amplifying cells differentiate into androgen-dependent transit (ie glandular) epithelial cells. Once the normal number of these androgen-dependent transit (glandular) cells is reached, their rate of cell proliferation balances their rate of cell death such that neither prostatic regression nor continuous glandular overgrowth occurs. Thus, in the presence of physiologic androgen, the normal prostate is in a steady-state, selfrenewing, heterogenously composed of androgen-independent, sensitive, and dependent epithelial cells.
For Isaacs et al 6, 7 in prostate cancer, castration results in a 'natural' selection of androgen-resistant cells. This hypothesis does not integrate some genetic alterations that are observed during the natural history of HRPC.
Hormone-refractory prostate cancer: multi-step and multi-event process
A more recent body of evidences suggests that HRPC is a multi-step and multi-event process 8 -10 (Figure 2 ).
Protein alterations
Bcl-2 family. Bcl-2 is expressed in the basal cells of prostatic glandular epithelium. 11 The majority of newly diagnosed prostate cancers do not express detectable levels of bcl-2 protein, however, progression of prostate carcinoma following androgen-ablation therapy is associated with the upregulation of bcl-2 expression. 12,13 Also, these tumours often demonstrate a resistance to chemotherapeutic interventions. Thus the potential survival advantage imparted by bcl-2 appears to be selected for following cytotoxic stresses resulting from therapeutic interventions. Bcl-2 positivity has been associated with increased rates of recurrence in prostate carcinoma and Figure 1 The selection hypothesis of hormone-refractory prostate cancer cells.
Hormone-refractory prostate cancer A de la Taille et al found to be an independent and additive predictive marker when examined together with Gleason score and seminal vesicle involvement. 14 Similarly, a retrospective assessment of pre-treatment levels of bcl-2 protein in prostate carcinomas from patients treated with radiation therapy suggested that bcl-2 may be predictive of a poor response. 15 Direct evidence of the contribution of bcl-2 to the resistance of prostate cancer to cell death induction has been provided by xenograft studies in which the expression of bcl-2 is enforced in androgen-sensitive prostate cancer cell lines. 16 Additionally, transgenic animal models in which bcl-2 has been selectively targeted to the prostatic glandular epithelium provide direct evidence of the participation of bcl-2 expression in prostate cancer progression in vivo. 17 Bcl-2 expression was also shown to confer resistance to chemotherapeutic cell death induction in prostate carcinoma cells. 18 The involvement of the proapoptotic member of the bcl-2 gene family, bax, in the progression and therapeutic resistance of prostate cancer has not been established although recent evidence suggests this may be the case. Upregulation of bax protein expression was temporally associated with apoptosis induction following castration in xenografts of the androgen sensitive cell line, LNCaP. 16 Additionally, increased expression of bax protein correlated with apoptosis induction in the rodent ventral prostate. 19 Furthermore, the DU145 prostatic cancer cell line has an inactivating mutation of the bax gene. 20 The latter observation suggests that bax may function as a tumour suppressor molecule in at least a subset of prostate cancers.
Androgen receptor. It was logical to investigate whether resistance to treatment was linked to an alteration in the androgen receptor (AR). The first important observation is that hormone resistance is not linked to the emergence of clones lacking receptors. Most hormone-resistant cancers conserve adequate concentrations of AR, although immunohistochemistry reveals heterogeneous receptor distribution. 38, 39 At an advanced stage, 85% of cancers contain at least 50% of immunopositive cells. 40 The AR content is more variable in high-grade cancer, and this may contribute to the altered response to hormone therapy. Another possible explanation for hormone resistance despite the persistence of AR is AR overexpression: indeed, gene amplification is often associated with the acquisition of resistance to therapeutic agents (for example, chemotherapy). Visakorpi et al 41 showed that amplification of the Xq11 -q13 region, in which the AR gene is situated, is frequent in tumours relapsing during androgen treatment (up to one-third of cases), but not in untreated tumours. Gene amplification could explain the high-level AR expression in some adenocarcinomas, and could facilitate the growth of tumour cells in the presence of residual androgen concentrations. Normally the AR is inactive until it is occupied by an androgen (dihydrotestosterone (DHT) in the prostate). However, steroid hormone receptors can be activated in the absence of hormone by phosphorylation. In the case of the AR, this possibility was demonstrated by Culig et al 9 In cells of the prostate tumour line DU-145 transfected with an AR expression vector (these cells are normally receptor-negative), the receptor can be activated by IGF-I as effectively as by the powerful synthetic androgen R-1881. Keratinocyte growth factor (a member of the fibroblast growth factor (FGF) family) and epidermal growth factor were also activated in some conditions. The action of these three growth factors was completely inhibited by a pure anti-androgen, bicalutamide. Thus, growth factor overexpression in prostate tumours may explain the persistence or resumption of a state emulating androgen stimulation in the absence of androgens. The rise in the tumour concentration of cyclic AMP can also potentiate the response to very low concentrations of androgens, thereby reducing the hormone concentration required for maximal stimulation by a factor of 100. 42 The first studies concluded that such mutations were rare: most changes were point mutations changing a single amino acid in the protein sequence. 38 Thereafter, technical advances showed a higher frequency of AR mutations in tumours having progressed to hormone resistance (44% according to Bentel and Tilley; 38 50% according to Taplin 43 ). Some point mutations of the AR gene have been studied from the functional viewpoint. The prototype of these AR mutations is seen in the androgen-sensitive cell line Figure 2 Hormone-refractory prostate cancer: a multi-step and multi-event process.
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A de la Taille et al LNCAP (lymph node cancer prostate). These cells carry a mutation at codon 877, in the hormone binding site, replacing a threonine by an alanine. 44 This mutation alters the specificity of the androgen receptor, making it capable of activation by several steroid hormones (progesterone, estradiol, etc) and also by anti-androgens such as flutamide. Nearly 24% of patients having undergone CAB treatment (superactive GnRH agonist þ flutamide, or castration þ flutamide) and whose cancer has reached the hormone escape stage, enter remission when flutamide is withdrawn. 45 It was shown that this 'flutamide withdrawal syndrome' was linked to mutations of the hormone-binding domain of the AR. 43, 46, 47 Other mutations can make the AR capable of activation by adrenal androgens (dehydroepiandosterone and androstenedione). 9, 48, 49 Another paradoxical situation is when advanced prostate adenocarcinomas resistant to hormone treatment react to androgen therapy. 50 These tumours have acquired a new phenotype following chronic androgen privation. The same phenotype has been reproduced experimentally in cell lines derived from various prostate tumours. 51 -53 The N-terminal region of the AR bears repeats of the CAO triplet coding for glutamine, and the GGC triplet coding for glycine. The length of polyglutamine sequences is normally between 8 and 31, with an average of 20, 54 and correlates negatively with AR transcriptional activity. A case -control study has effectively shown a link between short CAG repeats and an increased risk of prostate cancer. 55 Moreover, patients with shorter repeat sequences were at a high risk of metastases and death. Another study showed a reduction in the risk of prostate cancer with each supplementary CAG repeat. 56 Similarly, patients with fewer than 16 GGN repeats had an increased risk of cancer when the two types of repeat were considered jointly, the subgroup with two short repeat sequences (CAG < 22 and GGN < 16) having twice the risk of developing cancer than the subgroup with two long repeats. The frequency of latent prostate cancer in Japan is the same as in the US, but the frequency of clinical cancer is eight times lower in Japan. A noteworthy proportion of Japanese men with latent cancer have mutations that inactivate AR (deletions and nonsense/missense mutations), which is not the case for American patients. 57 Similarly, a constitutive amino acid substitution replacing the valine codon at position 89 by a leucine in the type 2 5a-reductase gene, that strongly reduces the activity of the enzyme, is very common in Asians and could explain the lower risk of prostate cancer in this population. 58 FAS/APO-1 protein. During a characterisation of monoclonal antibodies made against human B-lymphocyte antigens, investigators found a particular antibody (anti-APO-1), that could rapidly induce apoptosis of B-lymphocytes when simply added to the medium of these cells. 59 This antibody recognises a 45 kilodalton protein on the surface of lymphocytes which was initially named APO-1, and this protein was subsequently found to be equivalent to an oncoprotein previously named fas. Fas/ APO-1 (by consensus, also referred to as CD-95) is protein with an external transmembrane and cytosolic (internal) domains that has since been shown to be involved in numerous forms of cytosolic actions by the mammalian immune system. The fas protein shares partial sequence and amino acid homology with other membrane proteins that can transduce a cell death response (exemplified by the tumour necrosis factor-a receptor and the low-affinity nerve growth factor receptor, p75), having conserved motifs in the external domain of the protein as well as a so-called conserved 'death' domain in the cytosolic region of the protein. 60 By binding to the external domains of fas proteins, anti-APO-1 antibody induces a clustering of fas protein on the cell surface and the fas cluster then initiates a cascade reaction in which several other cytosolic proteins (TRADD, FADD/Mort 1 and RIP) attach onto the internal domain of the fas protein. Ultimately, the end result of this cascade aggregation is the activation of a cysteine-specific protease, caspase 8 which may be one of the ultimate 'executioner' molecules in the process of apoptosis. In natural situations, the fas/CD95 protein is the receptor for a ligand (fas ligand or fas-L) that is present on the surface of cytotoxic T-cells. Cytotoxic T-cells use their fas ligand, when stimulated, to cluster the fas receptor of target cells, initiating their apoptosis and elimination from the body. 60 Mutations in the fas receptor or ligand can result in the development of severe autoimmune diseases.
Mutations of the fas gene might be involved in proliferative diseases of the prostate by prolongation of programmed cell death of prostatic epithelial cells. Using the laser capture microdissection method, fas gene mutations were examined on genomic DNA extracted from high-grade prostatic intraepithelial neoplasia (HGPIN), and from PCA. LOH was found in 31.3% of PCA and 25% of HGPIN lesions, but was not found in benign glands. 93 Exclusive occurrence of fas mutations in HGPIN might underlie the development of these lesions.
Fas is expressed in several prostatic carcinoma cell lines but its in vivo expression in normal prostate and in prostate cancer is poorly understood. Diaz et al 94 showed that fas was expressed in all organ-confined tumours and in two out of six metastatic tumours (33%). Fas expression was significantly decreased in prostate cancer compared with benign prostate. The decrease was inversely related to the malignant grade of the tumours. Decreased expression of fas appears to be an early molecular event in prostate cancer. The decline begins in low-grade tumours. The lowest expression occurs in metastatic carcinomas, which are often fas negative.
Genetics alterations
Consistent molecular alterations have been observed during the development and progression of prostate cancer. One key gene alteration observed in androgenindependent prostate cancer is p53 gene mutations. Additional frequent molecular alterations observed in prostate carcinoma involve retinoblastoma suppressor gene (Rb), c-myc, and p21waf1/cip1. Loss of the heterozygosity (LOH) on chromosomes 7q, 8p, 10, 16q and 18q imply the existence of additional tumour suppressors that may be important in the pathogenesis of prostate cancer, such as the recently identified candidate tumour suppressor gene, PTEN/MMAC.
Tumour suppressor p53. The p53 tumour suppressor product is a transcription factor that functions in cell-cycle regulation, DNA repair, and programmed cell death, or apoptosis. In response to DNA damage, p53 functions either to inhibit the cell continuing the cell cycles enabling the cell to repair the DNA, or to trigger an apoptotic signal that mediates the selective deletion of the affected cell. 21 The identification of p53 responsive genes that mediate these outcomes is a matter of widespread interest. The p53-dependent transcriptional regulation of p21waf1/cip1 is an important event for mediating G1 cell-cycle arrest in response to genotoxic damage ( Figure  3 ). 22 It has been shown that wild-type p53 is able to transcriptionally upregulate the cell-death effector of the bcl-2 family, bax, and potentially downregulate bcl-2 itself. 23 Furthermore, bcl-2 protein expression was increased specifically in prostatic glandular epithelial cells in p53-deficient mice. 23 Since the ratio of bcl-2 to bax is believed to be an important determinant of cell death susceptibility, it may be considered that p53 protein regulates apoptosis by modulating the expression of bcl-2 family members. It has also been suggested that a deficiency of bax promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. 24 Somatic mutations in p53 have been identified in diverse types of cancer. The induction of p53 following irradiation may exhibit cell-type specificity in cells isolated from human prostate tissue. Epithelial cells derived from normal prostate, benign prostatic hyperplasia, and adenocarcinoma showed no evidence of p53 protein accumulation following radiation however, in stromal cells derived from the same patients, increased levels of p53 protein were observed. 25 The p53 gene is located on the short arm of chromosome 17, and it has been reported that LOH on chromosome 17 occurs in approximately 20% of prostate cancers. 26 Somatic mutations within p53 most commonly occur in the DNA-binding domain, but have also been identified in the carboxyl-terminal nuclear localisation domain, transactivation domain, and oligomerisation domain. Mutations in the p53 gene typically result in an increased half-life of the p53 protein, which then enables its detection by immunohistochemical methods, whereas wild type p53 protein is difficult to detect under these same conditions. These mutations usually result in the loss of function of p53 protein and consequent reduction in cell-cycle control and increased instability in genomic integrity. The reported incidence of p53 gene mutations in localised prostate cancer varies considerably, ranging from zero to 80%. 27 It is not surprising, therefore, that the significance of p53 gene mutations in localised prostate cancer is controversial. Recent immunohistochemical evidence suggests that the frequency of p53 gene mutations in prostate cancer from radical prostatectomy specimens varies between 47% and 80%. 28, 29 Additionally, Yang et al., have demonstrated that clustered p53 protein immunoreactivity in localised prostate cancer is correlated with a higher incidence of tumour recurrence in comparison to comparable lesions that lack evidence of p53 gene mutations. 30 There is arguably more consistent evidence that p53 gene mutations contribute to the progression of prostate cancer. It has been shown that p53 protein expression is correlated with a higher Gleason score, nuclear grade, pathological stage, and proliferation in localised primary prostate carcinomas and that there is an increase in p53 Figure 3 Cell cycle regulation by p53. Transcriptional activation of p53 results in both G1 and G2 arrest. p53 mediated transcriptional induction of p21WAF1/CIP1 plays a major role in mediating the G1 arrest. p21WAF1/CIP1 binds to and inhibits cyclin/cdk complexes resulting in the accumulation of hypophosphorylated Rb leading to G1 arrest. Gadd45 has been found to mediate the G2 arrest. Both Gadd45 and p21WAF1/CIP1, through their interaction with PCNA, may play a role in DNA repair. Wild-type p53 protein is able to transcriptionally upregulate the cell-death effector of the bcl-2 family, bax, and potentially downregulate bcl-2 itself.
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A de la Taille et al gene mutations in advanced prostate cancer, with the highest incidence occurring in androgen-independent tumours. 27, 30, 31 Several other studies have demonstrated that p53 protein expression serves as an adverse prognostic indicator in prostate cancer. 29, 32, 33 The contribution of p53 protein inactivation to the resistance of prostatic epithelial cells to the effects of androgen deprivation is incompletely understood. In this regard, recent observations indicate that the level of p53 mRNA and protein increases in the regressing rat ventral prostate following castration. 34 This enhanced expression of p53 appears to be associated with re-entry of the prostatic epithelial cells into a detective cell cycle, and may be important for the subsequent induction of apoptosis. 35 Other reports suggest that the significance of p53 in this context is related to DNA repair processes and is not associated with the molecular events of cell-cycle re-entry. 36 Subsequent observations from p53 'knockout' mice indicate that postcastration elevations of p53 protein enhance the rate of cell death in the prostate but are not essential for cell death induction. 37 In the literature, it is now clear that in prostate cancer the expression or otherwise in p53 is not so important as in other urological cancer.
Retinoblastoma suppressor gene. Molecular alterations in tumour suppressor genes and oncogenes that regulate cell-cycle progression have been observed in prostate cancer. The retinoblastoma suppressor gene product (Rb) is a nuclear phosphoprotein which regulates cell cycle progression in a phosphorylation dependant manner. In its dephosphorylated state, Rb binds to the transcription factor E2F and thereby blocks the cell in G1 and inhibits the progression into S phase. It is estimated that 20% of prostate cancers possess Rb mutations, and this number could increase due to the LOH on chromosome 13 involving the Rb locus. 61 However, it is arguable as to whether Rb gene inactivation is a primary event in the pathogenesis of prostate cancer or a secondary event associated with disease progression. 62, 63 c-myc. The c-myc proto-oncogene product is a nuclear phosphoprotein transcription factor necessary for cellcycle progression. Activation of an apoptotic cell death cascade occurs in cells if c-myc expression is enforced. Involvement of the proto-oncogene c-myc in multistep carcinogenesis was first demonstrated in Burkitt's lymphoma, in which the t(8; 14) translocation results in c-myc gene deregulation. Overexpression of c-myc mRNA has also been observed in several cell lines derived from colon carcinoma, promyelocytic leukemia and prostate carcinoma. Prostate cancers have been shown to express higher amounts of c-myc compared with normal prostate tissue or benign prostatic hyperplasia. 64, 65 Evaluation of case-matched prostate cancer biopsies from patients undergoing androgen ablation suggests that levels of cmyc expression increased following castration. 66 Similar elevations in the level of c-myc expression have been observed in the rodent prostate following castration. The significance of this augmentation in c-myc expression following androgen deprivation is not established. It is conceivable that increased levels of c-myc following hormone ablation are responsible for initiating an apoptotic cascade in androgen-dependent prostatic glandular epithelial cells. It is noteworthy in this regard that c-myc has been shown to directly transcriptionally regulate p53. However, it is arguable as to whether c-myc initiated cell death is completely dependent on the presence of wildtype p53. 67
p21. The p21WAF1/CIP1 gene product is a cyclin kinase inhibitor that can induce G1 arrest. The p21WAF1/CIP1 protein functions through inactivation of cyclin-dependent kinases and proliferating-cell nuclear antigen and is known to be regulated by p53. The loss of p21WAF1/ CIP1 activity may contribute to prostate cancer progression in that the p21WAF1/CIP1 gene is localised to chromosome 6p21.2 and LOH involving 6p has been demonstrated in prostate cancer. 68 Overexpression of p21WAF1/CIP1 has been shown to cause G1 arrest and thereby to suppress tumour cell growth. It has also been demonstrated that p21WAF1/CIP1 transcription is activated by wild-type p53. Rapid induction of p21WAF1/ CIP1 is observed following high-dose UV irradiation, which stabilises the p53 protein. However, the role of p21WAF1/CIP1 in apoptosis induction remains somewhat controversial, so the effects of p21WAF1/CIP1 on apoptosis may be context-dependent. A single-strand conformation polymorphism (SSCP) analysis of primary prostate cancers that lacked demonstrable p53 mutations revealed that 18% of the tumours possessed p21 mutations. 68 In contrast, an immunohistochemical evaluation of p21WAF1/CIP1 protein in a series of 40 prostate cancers revealed no correlation between p21WAF1/CIP1 immunoreactivity and tumour progression, grade, or stage. 69 It is noteworthy that the anti-p21 antibody used in this study may recognise wild-type and/or mutant p21WAF1/CIP1 protein. Similarly, in a polymerase chain reaction-SSCP analysis of 32 primary prostate cancers, only one was found to have alterations of the p16 gene. 70 There was no evidence of mutations involving p15, p18, or p19 genes. On the basis of these observations, the potential contribution of p21WAF1/CIP1 inactivation, or the inactivation of other cyclin-dependent kinase inhibitors, to the pathogenesis of prostate cancer remains undefined.
Ras. The Ras gene family consists of three functional genes and two pseudogenes, which are H-ras-1, K-ras-2, and N-ras and H-ras2 and K-ras-1, respectively. The members of this gene family are identical at their Ntermini and possess regions of significant homology. The function of ras in signal transduction is mediated by GTP/GDP binding. The overexpression of ras gene products is a common occurrence in human tumours and is typically a consequence of the acquisition of activating somatic mutations. Ras mutations were infrequent in latent carcinomas of the prostate discovered at autopsy, occurring in approximately 14% of these neoplasms. 71 The incidence of ras mutations was limited to 24% in clinically diagnosed prostate cancer. 72 The potential contribution of activating ras mutations to the pathogenesis of prostate cancer has been demonstrated using a mouse prostate reconstitution (MPR) model system. 73 In this model, reconstituted mesenchymal and epithelial cells from the fetal urogenital sinus are implanted under the renal capsule of adult male mice and subsequently develop into ectopic prostatic glandular tissue. H-ras or cmyc retrovirally infected fetal prostatic precursor cells developed epithelial hyperplasia in the MPR model. Prostate carcinomas rapidly developed if the urogenital sinus epithelial cells were infected with both H-ras and myc. 73 Additionally, p53 mutations were found in prostate glands containing activated ras alone but not in those transduced with both ras and myc. 74 LOH. LOH involving specific chromosomes has been demonstrated in prostate carcinomas. 75 The most commonly observed LOH involved 16q and 10q, with 30% of the examined cases demonstrating losses. 76 Additional LOH loci in prostate cancer included 3p, 7q, 9q, 10p, 10q, 11p, 13q, 16p, 16q, 17p and 18q. Of the cohort of cases examined, 54% of primary prostate carcinomas and 100% of metastatic carcinomas showed at least one locus affected by LOH. Similar findings have been reported by other groups, including the frequent involvement of 8p by LOH. 77 LOH was also more extensive in recurrent cancers compared with primary localised tumours. 78 The functional consequences of LOH for tumorigenicity and apoptosis induction on prostate carcinoma cells can also be examined prior to identification of a specific tumour suppressor gene using microcell hybrids containing 10pter -q11. Together, these studies imply the existence of multiple potential tumour suppressor genes that may contribute to the pathogenesis of prostate cancer.
MMACI/PTEN. Allelic loss of the long arm of chromosome 10 is detected in 30 -60% of prostate carcinomas, as well as high-grade glioblastomas, kidney and breast carcinomas, and melanoma. 79 A gene, MMACI, or PTEN, has recently been cloned from the critical region 10q23 that was identified by homozygous deletions in DNA from brain and breast tumours. LOH at the MMACI/PTEN locus has been observed in 29 -42% of prostate tumours, and screening for homozygous deletion of the gene identified a second mutational event in 43% of the prostate tumours. LOH of 10q was found in 11 out of 60 tumours (18%) that were localised to the prostate, but in 12 out of 20 pelvic metastases (60%). 80 This observation suggests that MMACI/PTEN may be an important tumour suppressor in a subset of prostate carcinomas, and that inactivation of MMACI/PTEN may be an important secondary genetic event that contributes to prostate cancer progression.
Neuroendocrine transdifferentiation
The epithelial cells of glands of the human prostate can be classified into any of three categories (basal, secretory epithelial or neuroendocrine) based upon their characteristic morphology, their location with regards to positioning adjacent to the basement membrane or lumen and their secretory activity. 81 The neuroendocrine cells (NE or endocrine-paracrine cells), although only a minor population of the epithelium, are known to produce and secrete some potent neuro-hormones that likely regulate the activity and homeostasis of the adjacent basal and/or secretory epithelial cells. 82 NE cells typically synthesise and secrete a number of growth factor-like agents (bombesin, calcitonin, parathyroid hormone-related peptide, etc) that have the ability to affect the proliferative rate and differentiation state of adjacent epithelial cells, whether benign or malignant. 83, 84 A number of recent clinical studies suggest that these NE cells might also have a role in prostate cancer development or progression. 85, 86 Histological comparisons between benign and neoplastic human prostate tissue revealed that NE cells are significantly more abundant in prostate cancers. 87 In fact, the overall abundance of NE cells has been reported to increase with progression of prostate cancer to advanced or hormone-resistant states. 88 Furthermore, comparisons of hormone-dependent and clinically advanced, hormone-independent prostate cancers found an increased of serum levels of chromogranin A 89 and NSE, 90 which are markers for NE cells.
These observations have led to the hypothesis that NE cells function as a provider of paracrine stimulatory factors that accelerate growth and progression of surrounding prostate cancer cells towards androgen-independent state. The hypothesis is strengthened by the observation of proliferating tumour cells in close proximity to NE cell foci. 83 Although the origin of the NE cell population of prostate cancers remains uncertain, a number of recent publications have established that prostate cancer cells themselves have the ability to 'transdifferentiate' (or convert) to a cell with a NE-like phenotype, in vitro. This can occur when cultured prostate cancer cells (LNCaP and PC-3) are exposed to agents that increase intracellular levels of cyclic AMP (cAMP), 91 by supplementation of cultures with interleukin-6 92 or when prostate cancer cells (LNCaP) are cultured in a medium deprived of steroid hormones (by use of a charcoal-striped serum supplement). 45 These treatments rapidly suppress cell growth while inducing a morphological change in the cellular phenotype so that they resemble cultured neuronal cells with narrow cell bodies and elongated processes. Electron microscopic evaluation of cells cultured under these conditions also identifies the presence of numerous secretory granules that are more typically found in NE cells. 45 Finally, examinations of the phenotypic characteristics of these cells show that they produce an excess of several NE cell gene products, including NSE, chromogranin A, bombesin and S-100. 45, 91 When the agent used to initiate the transdifferentiation process is hormone depleted medium, the cells also lose their prostate cell characteristics with reduced expression of androgen receptors and prostate specific antigen. 45 Collectively, these findings suggest the possibility that the NE cells associated with human prostate cancer might actually arise due to the transdifferentiation of a subpopulation of the prostate cancer cells in vivo. Likewise, the ability of hormone depleted medium to induce the NE phenotype in cultured prostate cancer cells 45 also suggests that therapies for prostate cancer involving hormone manipulation might be the cause for the increased NE cell numbers found in tumours of advanced prostate cancer patients.
Conclusion
Over the past decade, apoptosis has become one of the foremost topics of interest and experimentation in science and medicine. Apoptosis is critical to the normal execu-tion of many biological processes and plays a key role in regulatory activities including development, immunology, neurobiology, oncology, pathology, aging, and many other essential biological processes. Defective apoptosis plays a role in the pathogenesis of number of disease processes, especially in HRPC. However, despite some new and interested molecular targets for therapeutic intervention, none of them today has a clinical implication. Further studies and research are needed in this field in order to propose in the near future new therapy for this incurable disease.
